(NASDAQ: ZNTL) Zentalis Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.23%.
Zentalis Pharmaceuticals's earnings in 2026 is -$149,316,000.On average, 11 Wall Street analysts forecast ZNTL's earnings for 2026 to be -$137,529,358, with the lowest ZNTL earnings forecast at -$231,253,068, and the highest ZNTL earnings forecast at -$98,622,313. On average, 9 Wall Street analysts forecast ZNTL's earnings for 2027 to be -$119,387,187, with the lowest ZNTL earnings forecast at -$155,064,622, and the highest ZNTL earnings forecast at -$78,897,851.
In 2028, ZNTL is forecast to generate -$98,940,217 in earnings, with the lowest earnings forecast at -$149,400,161 and the highest earnings forecast at -$12,138,131.